Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission

This study follows patients with chronic myeloid leukemia (CML) — a type of blood cancer — who have achieved a deep, long-term response to treatment and are attempting to stop their medication (called treatment-free remission). Researchers want to understand what happens to their disease over time after stopping therapy. **You may be eligible if:** - You are 20 or older with chronic phase CML - You have been on imatinib for at least 5 years, or on a second-generation TKI (nilotinib or dasatinib) for at least 4 years continuously - You have achieved a very deep molecular response (undetectable or near-undetectable cancer in the blood) for at least 2 years, confirmed on multiple tests - You have access to a reliable molecular test to monitor your disease **You may NOT be eligible if:** - You have had documented resistance to second-generation TKIs - You have not achieved the required depth of molecular response - You do not have access to the required sensitive monitoring test Talk to your doctor to see if this trial is right for you.